Filtered By:
Drug: Metformin
This page shows you your search results in order of relevance. This is page number 11.
Order by Relevance | Date
Total 6409 results found since Jan 2013.
Polycystic ovarian syndrome and miscarriage in IVF: systematic revision of the literature and meta-analysis
ConclusionPCOS is linked to an increased MR in IVF pregnancies both of miscarriages in total, and to an increase in preclinical and early miscarriages.Prospero numberCRD42020186713.
Source: Archives of Gynecology and Obstetrics - September 4, 2022 Category: OBGYN Source Type: research
Impact of Chinese Herbal Medicine on Glucolipid Metabolic Outcomes in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis
CONCLUSION: Compared with the placebo group, Chinese herbal medicine had positive effects on glucolipid metabolism in women with PCOS. Chinese herbal medicine had a positive effect on lipid metabolism when the control group was metformin, but no effect on glucose metabolism. These findings need to be verified in high-quality, large-sample, randomized controlled trials in the future.PMID:36212945 | PMC:PMC9546672 | DOI:10.1155/2022/3245663
Source: Evidence-based Complementary and Alternative Medicine - October 10, 2022 Category: Complementary Medicine Authors: Jie Li Ruqun Zheng Zixin Lin Fangyuan Hu Ying Lin Guomei Zeng Jieni Fang Yingyan Shen Huiyan Tan Mei Han Juan Li Source Type: research
SPIOMET4HEALTH —efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome: study protocol for a multicentre, randomised, double-blind, placebo-controlled, fo ur-arm, parallel-group, phase II clinical trial
DiscussionThe present study will be the first to evaluate —in a randomised, double-blind, placebo-controlled way—the efficacy, tolerability and safety of SPIOMET treatment for early PCOS, on top of a lifestyle intervention.Trial registrationEudraCT 2021 –003177-58. Registered on 22 December 2021.https://www.clinicaltrialsregister.eu/ctr-search/search?query=%092021-003177-58.
Source: Trials - September 15, 2023 Category: Research Source Type: clinical trials
Targeting impaired nutrient sensing with repurposed therapeutics to prevent or treat age-related cognitive decline and dementia: a systematic review
CONCLUSIONS: Modulation of nutrient sensing pathway therapeutics, particularly growth hormone secretagogues, have the potential to improve cognitive outcomes. Overall, there is a clear lack of translation from animal models to human populations.PMID:33609776 | DOI:10.1016/j.arr.2021.101302
Source: Ageing Research Reviews - February 20, 2021 Category: Genetics & Stem Cells Authors: Benjamin Kioussis Camilla S L Tuttle Daniel S Heard Brian K Kennedy Nicola T Lautenschlager Andrea B Maier Source Type: research
Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option
CONCLUSION: There are treatments available for antipsychotic-induced hyperprolactinemia in patients who are unable to alter their current antipsychotic regimen. However, there remains a need for additional short- and long-term studies to determine the efficacy and safety of these treatment strategies, given that patients taking antipsychotics typically require chronic, life-long treatment for their illnesses.PMID:33631819 | DOI:10.1093/ajhp/zxab065
Source: American Journal of Health-System Pharmacy : AJHP - February 25, 2021 Category: Drugs & Pharmacology Authors: Matthew M Rusgis Afaq Y Alabbasi Leigh Anne Nelson Source Type: research
Mechanisms and Potential Roles of Glucose-Lowering Agents in COVID-19: A Review
CONCLUSIONS: Certain glucose-lowering agents may offer additional benefits beyond glucose control-namely, by modulating the mechanisms contributing to adverse outcomes related to COVID-19 in patients with diabetes. DPP-IV inhibitors and metformin appear to have the most promise. However, current published literature on diabetes medications and COVID-19 should be interpreted with caution. Most published studies are retrospective and consist of convenience samples, and some lack adequate analytical approaches with confounding biases. Ongoing trials aim to evaluate the effects of glucose-lowering agents in reducing the severi...
Source: The Annals of Pharmacotherapy - March 4, 2021 Category: Drugs & Pharmacology Authors: Helen D Berlie Pramodini B Kale-Pradhan Tara Orzechowski Linda A Jaber Source Type: research
Pharmacological and non-pharmacological strategies for obese women with subfertility
CONCLUSIONS: Evidence is insufficient to support the use of pharmacological and non-pharmacological strategies for obese women with subfertility. No data are available for the comparison of pharmacological versus non-pharmacological strategies. We are uncertain whether pharmacological or non-pharmacological strategies effect live birth, ongoing pregnancy, adverse events, clinical pregnancy, quality of life, or mental heath outcomes. However, for obese women with subfertility, a lifestyle intervention may reduce BMI. Future studies should compare a combination of pharmacological and lifestyle interventions for obese women w...
Source: Cochrane Database of Systematic Reviews - March 25, 2021 Category: General Medicine Authors: Seyed Abdolvahab Taghavi Madelon van Wely Shayesteh Jahanfar Fatemeh Bazarganipour Source Type: research
The effects of myo-inositol vs. metformin on the ovarian function in the polycystic ovary syndrome: a systematic review and meta-analysis
CONCLUSIONS: Due to the dearth of related research and the high heterogeneity of the Randomized Clinical Trials (RCTs) included in other studies, the present systematic review could not establish any differences between metformin and myo-inositol concerning the hormonal profile and the ovarian function. However, the findings indicated that myo-inositol could improve fertility outcomes by modulating hyperandrogenism. Randomized trials are required to understand the mechanistic actions of myo-inositol in comparison with those of metformin regarding oocyte and embryo quality, fertilization, pregnancy, and live birth rates.PMI...
Source: Pharmacological Reviews - April 20, 2021 Category: Drugs & Pharmacology Authors: M Azizi Kutenaei S Hosseini Teshnizi P Ghaemmaghami F Eini N Roozbeh Source Type: research
Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
Expert Rev Clin Pharmacol. 2021 Apr 22:1-16. doi: 10.1080/17512433.2021.1917374. Online ahead of print.ABSTRACTIntroduction: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are significant non-communicable diseases that often affect individuals concurrently. In individuals with both T2DM and NAFLD, there is evidence that anti-diabetic therapies may demonstrate potential combined beneficial metabolic and reduced hepatic inflammatory effects.Areas covered: A PubMed and Google Scholar search was performed to find relevant literature. Included studies focused on individuals with T2DM and NAFLD rece...
Source: Pharmacological Reviews - April 22, 2021 Category: Drugs & Pharmacology Authors: Elizabeth M Lamos Megan Kristan Maka Siamashvili Stephen N Davis Source Type: research
The effects of myo-inositol vs. metformin on the ovarian function in the polycystic ovary syndrome: a systematic review and meta-analysis
CONCLUSIONS: Due to the dearth of related research and the high heterogeneity of the Randomized Clinical Trials (RCTs) included in other studies, the present systematic review could not establish any differences between metformin and myo-inositol concerning the hormonal profile and the ovarian function. However, the findings indicated that myo-inositol could improve fertility outcomes by modulating hyperandrogenism. Randomized trials are required to understand the mechanistic actions of myo-inositol in comparison with those of metformin regarding oocyte and embryo quality, fertilization, pregnancy, and live birth rates.PMI...
Source: Pharmacological Reviews - April 20, 2021 Category: Drugs & Pharmacology Authors: M Azizi Kutenaei S Hosseini Teshnizi P Ghaemmaghami F Eini N Roozbeh Source Type: research
Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
Expert Rev Clin Pharmacol. 2021 Apr 22:1-16. doi: 10.1080/17512433.2021.1917374. Online ahead of print.ABSTRACTIntroduction: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are significant non-communicable diseases that often affect individuals concurrently. In individuals with both T2DM and NAFLD, there is evidence that anti-diabetic therapies may demonstrate potential combined beneficial metabolic and reduced hepatic inflammatory effects.Areas covered: A PubMed and Google Scholar search was performed to find relevant literature. Included studies focused on individuals with T2DM and NAFLD rece...
Source: Pharmacological Reviews - April 22, 2021 Category: Drugs & Pharmacology Authors: Elizabeth M Lamos Megan Kristan Maka Siamashvili Stephen N Davis Source Type: research
